SPRY (ARS Pharmaceuticals) Earnings per share growth rate in current year
Geopolitical instability may disrupt component supplies and complicate global drug certification. However, ARS Pharmaceuticals (SPRY) relies on a unique nasal spray, the demand for which guarantees a stable cash flow. Production risks are mitigated by outsourcing packaging to external partners and establishing reserves. The proportional growth in EPS compared to last year demonstrates profitability dynamics, where the current mark equals -4.00.
Analytical breakdowns and data insights for company ARS Pharmaceuticals (SPRY)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt and liquidity details:
All Debt to Shareholders' Equity Ratio ARS Pharmaceuticals|SPRY - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient ars-pharma.com|SPRY - Company Total Debt|Debt to Net Assets Ratio ARS Corp|SPRY - Company Long-Term Debt|Current Liabilities ARS Pharmaceuticals|Intermediate Coverage Ratio ars-pharma.com
- net income and valuation multiples indicators:
SPRY - Net Profit|Projected Future Earnings ARS Pharmaceuticals|SPRY - Price to Earnings Ratio|Future Price to Earnings Multiple ARS Corp|SPRY - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio ARS Corp|SPRY - Operating profit EBITDA|Net earnings per share (EPS TTM) ARS Pharmaceuticals|SPRY - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months ars-pharma.com|SPRY - Earnings growth in current year|Expected net earnings per share growth next year ARS Pharmaceuticals
Summary company analysis:ARS Pharmaceuticals Inc (SPRY)
This indicator measures the year-over-year dynamics of net earnings per share, allowing for an assessment of business scaling efficiency and the accuracy of management's financial plan execution. By analyzing the EPS comparison with the previous year, an investor can correlate profit growth rates with the commercialization of needle-free delivery systems, specifically the Neffy nasal spray, which determines the investment attractiveness of ARS Pharmaceuticals (SPRY).
Main competitors
Haleon PLC - Earnings per share increase in current year|KVUE (Kenvue Corp) - Earnings growth in current year|Earnings per share growth rate in current year Verona Pharma Inc. VRNA|Earnings per share growth in current year Jyong Biotech Ltd (MENS)|LGND (ligand.com) - Earnings per share increase in current year|Earnings growth in current year AMRX (Amneal)|Earnings growth in current year Perrigo Company PLC PRGO|ALVO - Earnings per share growth in current year|Earnings per share increase in current year LQDA (Liquidia Inc.)|Galapagos NV (GLPG) - Earnings per share growth in current year|ANIP - Expected net earnings per share growth this year|Net earnings per share growth this year MNKD|AMPH: Earnings per share increase in current year|Earnings per share growth in current year Pacira (PCRX)|TBPH: Earnings per share trend in current year|Earnings growth in current year AQST (Aquestive Therapeutics)|Earnings per share increase in current year SCPH|Tectonic - Earnings growth in current year|TNXP - Earnings growth in current year|sxtchina.com (SXTC) - Earnings per share growth in current year|Eupraxia Pharmaceuticals Inc. - Earnings per share increase in current year|Earnings per share growth in current year BioHarvest Sciences|Net earnings per share growth this year invizyne.com (EXOZ)|Earnings growth in current year ORMP|Earnings growth in current year enterabio.com (ENTX)|Earnings growth in current year HYFT (MindWalk)|ABVC - Net earnings per share growth this year|Cumberland Pharmaceuticals - Earnings growth in current year|Earnings per share growth rate in current year quantumbiopharma.com|FGEN (FibroGen) - Net earnings per share growth this year|Telomir Pharmaceuticals Inc (TELO) - Earnings growth in current year|Net earnings per share growth this year RANI|SNYR (Synergy CHC Corporation) - Net earnings per one share growth for the current year|Earnings growth in current year RLYB|Expected net earnings per share growth this year lexariabioscience.com|Earnings growth in current year PULM (Pulmatrix)|PTHL - Net earnings per share growth this year|Aptorum - Earnings growth in current year|LYRA - Earnings growth in current year|Impact BioMedical (IBO) - Earnings per share growth in current year|TNFA (TNF Pharmaceuticals, Inc.) - Earnings per share growth in current year|Earnings per share growth in current year cbdMD Inc.|PainReform Ltd (PRFX) - Expected net earnings per share growth this year|Earnings per share growth in current year Altamira Therapeutics (CYTO)|Expected net earnings per share growth this year Lipella Pharma|Earnings per share growth in current year OptiNose, Inc. OPTN|PIRS (pieris.com) - Earnings per share trend in current year|PROC - Earnings per share growth in current year|Earnings per share increase in current year PTPI (Petros Pharmaceuticals Inc)|QLI (Qilian International Holding Group Limited) - Net earnings per share growth this year|Earnings per share growth rate in current year ACELYRIN Inc. (SLRN)|Earnings per share growth in current year TFF Pharmaceuticals
